

Corimmun Has Successfully Completed a Phase I Clinical Trial with its Lead Compound COR-1

Martinsried/Munich, Germany, March 15, 2010 -- Corimmun GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of cardiovascular diseases, today announced the successful completion of a Phase I clinical trial with its lead compound COR-1. All five investigated dose groups were well tolerated, no drug-related side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete serum clearance within 60 minutes after administration. Pharmacodynamic investigation showed dose-dependent efficacy with almost complete scavenging of pathological anti- β 1 receptor auto-antibodies at the two highest doses.

The trial was designed as a randomized, single blind, placebo-controlled study, and was conducted in Germany. 50 male human volunteers between 18 and 45 years received COR-1 or matching placebo intravenously as single intravenous administrations with ascending doses. Primary endpoints were safety and tolerability, while the pharmacokinetics profile of COR-1 was assessed as a secondary endpoint. Pharmacodynamic investigation showed *ex vivo* efficacy with almost complete scavenging of pathological anti- β 1 receptor auto-antibodies at the two highest doses. No anti-COR-1 autoantibodies occurred.

"We are happy about the positive results of this trial," said Götz Münch, CEO of Corimmun. "The resulting data provide an excellent basis to start a Phase IIa clinical trial with COR-1 in patients."

COR-1 is a cyclic peptide with a unique mode of action. It is developed by Corimmun for the personalized treatment of heart failure, and targets the auto-immune mechanism of antibodies directed against the β 1-adrenergic receptor in these patients. COR-1 is a drug which prevents this auto-antibody-mediated propagation of heart failure. Functional auto-antibodies are an increasingly recognized phenomenon in any form of heart failure, corresponding to a large and currently unmet medical need.

In contrast to existing drugs used in the treatment of heart failure, COR-1 does not result in any acute negative effect on hemodynamics (such as lowering blood pressure or pulse rate) which often causes side effects with these existing drugs.

Notes to Editors

About COR-1:

Corimmun's lead product COR-1 is a cyclic peptide. It targets autoantibodies directed against the human β 1-adrenergic receptor. As a result, these auto-antibodies are inactivated and cardiac performance improves.

COR-1 has a short half-life. COR-1 has been validated in relevant animal models and has shown strong efficacy in terms of decrease of immune reaction and improvement of heart failure (clinical symptoms as well as hemodynamic parameters).

About Corimmun

Corimmun GmbH (www.corimmun.com) is a private biotechnology company located in Martinsried near Munich, Germany, which focuses on cardiovascular diseases with unmet medical need. For these indications, Corimmun currently develops various projects in preclinical and clinical stage. The company receives constant scientific support from the outstanding university groups of the company's founders. In 2008, Corimmun successfully closed its Series A financing round, led by MIG Funds (www.mig.ag) with KfW, Bayern Kapital and High-Tech Fonds as Co-Investors.

Contact

Dr. Götz Münch, CEO Corimmun GmbH
Tel: +49-89-8565 2010
Email: muench@corimmun.com